Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options

Manuscript Number: 

18-0766R1

Author(s): 
Clive G. Ballard, Jeffrey Cummings, Gary Tong

Disclosures

Clive G. Ballard

  • Consulting Fees:
    Consulting fees from Acadia Pharmaceuticals, Eli Lilly, Lundbeck, Novartis, Otsuka, Pfizer, Roche
    Grants
    • Agency: 
      Acadia Pharmaceuticals
    • Agency: 
      Lundbeck

Jeffrey Cummings

  • Consulting Fees:
    Dr. Cummings has provided consultation to Acadia, Accera, Actinogen, Alkahest, Allergan, Alzheon, Avanir, Axsome, BiOasis Technologies, Biogen, Bracket, Denali, Diadem, EIP Pharma, Eisai, Forum, Genentech, Green Valley, Grifols, Hisun, Idorsia, Kyowa Kirin, Lilly, Lundbeck, MedAvante, Merck, Otsuka, Pain Therapeutics, Proclara, QR, Resverlogix, Roche, Samus, Sunovion, Suven, Takeda, Teva, Toyama, and United Neuroscience pharmaceutical and assessment companies.
    Equity:
    Dr. Cummings owns stock in ADAMAS, BioAsis, Prana, MedAvante, Neurokos, and QR Pharma.
    Patents/Royalties
    Dr. Cummings owns the copyright of the Neuropsychiatric Inventory (NPI).
    Grants
    • Agency: 
      Avid (In-kind research support)
      Dates: 
      2016-2019
    • Agency: 
      Teva (In-kind research support)
      Dates: 
      2016-2019

Gary Tong

  • Sponsors:
    US therapeutic area head for dementia for Lundbeck